Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Summary Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII, porcine sequence, with low cross‐reactivity to anti‐hFVIII antibodies. Efficacy can be monitored with FVIII...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Haemophilia : the official journal of the World Federation of Hemophilia Ročník 21; číslo 2; s. 162 - 170
Hlavní autori:	Kruse-Jarres, R., St-Louis, J., Greist, A., Shapiro, A., Smith, H., Chowdary, P., Drebes, A., Gomperts, E., Bourgeois, C., Mo, M., Novack, A., Farin, H., Ewenstein, B.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Blackwell Publishing Ltd 01.03.2015 Wiley Subscription Services, Inc
Predmet:	acquired haemophilia A Adult Aged Aged, 80 and over Animals Antibodies, Neutralizing Autoantibodies Autoantibodies - immunology Bleeding bleeding episodes Coagulation factors Cross Reactions - immunology Dosage Factor VIII - administration & dosage Factor VIII - adverse effects Factor VIII - immunology Factor VIII - therapeutic use Female Hemophilia Hemophilia A - drug therapy Hemophilia A - immunology Humans Hypersensitivity Male Middle Aged recombinant FVIII porcine sequence Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Recombinant Proteins - immunology Recombinant Proteins - therapeutic use replacement therapy Swine Thrombocytopenia Time Factors Treatment Outcome acquired haemophilia A bleeding episodes recombinant FVIII porcine sequence replacement therapy
ISSN:	1351-8216, 1365-2516, 1365-2516
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!